Skip to main content

BioTrove, Gene Express to Co-Market Lung Cancer Risk Test

NEW YORK (GenomeWeb News) – BioTrove and Gene Express have struck an agreement to co-market a test for profiling certain indicators for the risk of lung cancer, BioTrove said today.
The test, called the Standardized NanoArray PCR, or SNAP, gene expression profiling system, uses BioTrove’s OpenArray nanofluidic PCR platform, Gene Express’ PCR measurement standards, and clinical knowledge from the University of Rochester School of Medicine and Dentistry.
The PCR analysis profiling system is a novel method for “consistent and accurate lung cancer risk analysis” that may be used in diagnostic laboratories or community hospitals, BioTrove said.
David Lester, Gene Express’ chief technology officer, said in a statement that the SNAP system “simplifies and standardizes” lab workflows and makes “genetic profiling viable and translatable” in diagnostic labs.
BioTrove’s OpenArray system allows scientists to conduct up to 3,072 independent PCR analyses simultaneously on up to 144 samples in a single plate, while Gene Express’ Standardized RT PCR, or StaRT-PCR, control for false negatives and false positives, BioTrove said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.